Water-soluble C₆₀ fullerene ameliorates astroglial reactivity and TNFα production in retina of diabetic rats

V. S. Nedzvetsky*, **, E. V. Sukharenko*, ***, G. Baydas****, G. V. Andrievsky*****

*Bingöl University, Bingöl, Turkey
**Oles Honchar Dnipro National University, Dnipro, Ukraine
***Kerch State Maritime Technological University, Kerch, Ukraine
****Altinbas University, İstanbul, Turkey
*****Institute of Physiological Active Compounds, Kharkov, Ukraine

Article info
Received 27.09.2019
Received in revised form 20.10.2019
Accepted 21.10.2019

Introduction

Diabetic retinopathy (DR) is one of widespread complications of diabetes as a result of glucose metabolism disturbance. In total, more than 40% of all diabetics and 60% of patients with diabetes have some degree of DR retinopathy 15 years after diagnosis of diabetes (Flaxman et al., 2011). In particular, inadequately controlled patients are a high risk group when the retinal microvasculature is permanently exposed to hyperglycemia. Both hyperglycemia and sudden changes in blood glucose content can provoke critical damage in endothelial and retinal cells, which induces hemorrhage, disbalance in neurovascularization, ischemic and neuroglial alterations (Giacco & Brownlee, 2010; Nedzvetsky et al., 2016).

Neurodegeneration is the main complication in the course of DR pathogenesis. Retinal cell decline occurs as a rule before microcirculatory disturbances which are clinically detectable (Rungger-Brandle et al., 2000). The mechanisms that initiate functional recession in the retina are extremely important for finding the molecular targets of both early stage and progression DR therapy. DR is clinically classified into proliferative and non-proliferative pathogenic stages. In the non-proliferative stage, retinal changes are associated with microaneurysms, vascular permeability, vessel closing and non-perfusion (Frank, 2004; Forbes & Cooper, 2013). Proliferative DR is characterized by new microvascular formation in the retinal surface, vitreous cavity and visual loss (Frank, 2009). Besides, visual impairment has been identified in diabetic patients in the early stages of diabetes (Rungger-Brandle et al., 2000). Hyperglycemia induces microvascular abnormality, retinal neurodegeneration and glial reactivity against cellular injury (Giacco & Brownlee, 2010). Molecular and cell injuries provoke early changes in all retinal cell layers, which take place before the first ophthalmoscopically detectable DR signs become visible (Rungger-Brandle et al., 2000; Giacco & Brownlee, 2010).

One of the well studied causes of DR associated with cellular damages is generation of oxidative stress in retinal cells. Besides, hyperglycemia-induced peroxynitrite formation in the retina can initiate production of proinflammatory factors and as a result retinal inflammation (Giacco & Brownlee 2010; Tang & Kern, 2011). Proinflammatory cytokines which are released from endothelial cells initiate retinal astrocytes and Muller cells reactivity, which is accompanied by production of free radicals, oxidative stress generation and retinal dysfunction (Ly et al., 2011; Coorey et al., 2012; Subinada et al., 2018). Other molecular disturbances are related to overexpression of vascular endothelial growth factor.
(VEGF), the initiation of retinal angiogenesis activates the interaction between endothelial cells and pericytes and abnormal blood vessel formation (Chavala et al., 2007; Grigsby et al., 2017; Lenini et al., 2018). DR progression is associated with Muller cell death (Feenstra et al., 2013). Furthermore, hyperglycemia induces endoplasmic reticulum stress in Muller cells, which activates inflammation and intercellular communication in the retina (Zhang et al., 2012; Sanchez-Chavez et al., 2016). All of these abnormalities stimulate glial cells to activate cellular response and gliosis, which is accompanied by the release of cytokines (Wang et al., 2012).

Thus, molecular and cellular disturbances in DR are associated with pro-inflammatory and pro-oxidative factors (Devi et al., 2012). The human retina consists of seven major cell classes, however only glial cells are capable of intense reactivity against various injuries. Retinal astrocytes and Muller cells are more prone to be reactivated by these factors as they are the main defences against various injuries in the retina (Rungger-Brandle et al., 2000; Asnaghi et al., 2003; Fukuda et al., 2010; Zhong et al., 2012).

Astrocytes are macroglial cells which play a critical role in many fundamental processes including neurogenesis, synaptic transmission and neuroprotection (Sofroniew & Vinters, 2010). In this respect, the control of astroglial reactivity could be an important target in treatment of DR complications. Abundant evidence supports the role of oxidative stress in the development and the progression of DR. Recently, the suppression of astroglial reactivity in the retina was demonstrated in rats with STZ-induced diabetes via PARP inhibition (Guzik, 2016). On the other hand, PARP inhibitors can ameliorate retinal inflammation (Kovacs et al., 2019). Further evidence of the beneficial effect of the limiting glial cells in the retina was obtained with curcumin exposure of diabetic rats (Zuo et al., 2013). Besides, curcumin possesses anti-inflammatory effect through NF-κB inhibition. Unfortunately, curcumin is a hydrophobic compound and cannot easily permeate the retinal blood barrier (Priyadarshini, 2014) and high doses of curcumin may lead to cytotoxicity (Hollborn et al., 2013).

The regulatory pathways associated with inflammation, triggering programmed cell death and cellular response including NF-kB and caspases, cytoskeleton rearrangement, may control the astrocyte reactivity and glial potential to repair hyperglycemia-induced cell injury. The suppression of astroglial reactivity in the retina may prevent progressive DR complications. The inhibition of glial overactivity could be realized in a variety of ways, especially by anti-inflammatory and antioxidant compounds. Some nutritional supplements including zeaaxanthin, lutein, lipoic acid, omega-3 fatty acids have been demonstrated as agents for limiting DR progression (Kowluru et al., 2014). Natural antioxidants have been recognized as the protectors against retinal neuroinflammation, oxidative stress and apoptosis in animal models of diabetes. However, natural flavonoids and polyphenols require the treatment in millimolar doses to achieve protective effect (Kowluru et al., 2007; Soufi et al., 2012; Kumar et al, 2013; Ola et al., 2018). On the other hand, some polyphenols may develop cytotoxic effect in micromolar concentration (Hollborn et al., 2013).

A new type of antioxidant is carbon nanoparticles, especially C60 fullerene, which have been confirmed as a promising compound in a number of biomedical studies (Takada et al., 2006). Unmodified C60 fullerene is recognized as an antioxidant and anti-inflammatory nanomaterial. Antioxidant features of C60 fullerene were demonstrated by in vivo and in vitro studies (Chari et al., 2005; Spohn et al., 2009). The anti-inflammatory effect of fullerene C60 was confirmed in the models of atopic dermatitis and arthritis (Dellinger et al., 2015; Shershakov et al., 2016). Moreover, neuroprotective properties were observed in the brain of rats with streptozotocin-induced diabetes (Nedzvetsky et al., 2012). Despite the numerous data on biomedical application of C60 fullerene nanoparticles, there is only one article dealing with the effect of unmodified hydrated C60 fullerene (C60HyFn) on DR disturbance (Nedzvetsky et al., 2016). Taking into account the anti-oxidant and anti-inflammatory features of unmodified C60 fullerene, this study was aimed at clarifying the potential of C60HyFn as a gliprotector against molecular disturbance in cellular reactivity in early stage of DR.

**Materials and methods**

The animals and streptozotocin-induced diabetes. Every experimental procedure was carried out in accordance with the guidelines for the care and the use of laboratory animals in the Principles of Laboratory Animal Care. The research protocols were reviewed and approved by the local ethical committee on the treatment of animals at the Dnipro State Medical Academy and Bingoli University.

Streptozotocin-induced diabetes (STZ-D) has been widely used as an adequate model for studying the neurodegenerative changes that occur as a result of impaired glucose utilization mechanisms. This study was carried out on 12–13 week old Wistar rats (males weighing 200–230 g), which were obtained from the vivarium of the Dnipro State Medical Academy. The animals were kept in controlled daylight hours (12/12 hours cycle) and constant temperature conditions (23 ± 2 °C). The water and the food were available to the animals ad libitum.

After 7 days of acclimation, 24 animals were randomly separated into 4 groups (n = 6): 1 – control group (C) (intact animals); 2 – “fullerene” control, the animals treated with C60HyFn solution with drinking water (C60HyFn); 3 – rats with STZ-diabetes (STZ-D); 4 – diabetic animals treated with C60HyFn solution with drinking water (STZ-D + C60HyFn). The animals were starved for 24 hours before hyperglycemia initiation. The third and fourth animal groups were given a single intraperitoneal injection of STZ (Sigma, St. Louis, MO, USA) in a dose of 55 mg/kg dissolved in 0.1 M sodium citrate buffer (pH 4.5) to induce experimental diabetes. Animals of the control group were injected with an appropriate volume of sodium citrate buffer. The second and fourth animal groups consumed a solution of 20 ng/ml C60 (corresponding to 30 nM C60 concentration) in drinking water for 12 weeks (from the onset of diabetes to decapsulation). The content of blood glucose, insulin and glycosylated hemoglobin. The rats were weighed weekly from the beginning to the end of the 12 week experiment. Venous blood glucose was measured with a glucometer (ACCU-Check Active, Roche Diagnostics, Mannheim, Germany) in blood from the tail vein for 3 days after STZ injection and every subsequent week. Only the animals with a blood glucose content of at least 20 mM/L were considered diabetic. 12 weeks after diabetes induction, rats of all groups were decapitated under diethylester anesthesia. The blood samples obtained during the 12 weeks were centrifuged at 3000 g for 10 min and serum was collected as individual samples. The content of glucose, insulin (Rat Insulin Kit, Linco Research, St. Charles, MO, USA) and glycosylated hemoglobin (HBAlc) (Alfabiotech, Milano, Italy) were measured with immunooassay (ELISA, Ex-800, BioTek Instruments, Winooski, VT).

**Protein extraction and western blot.** The retina from both eyes was separated to obtain protein extract. Retinal homogenates (1:10, w/v) were prepared in 25 mM Tris buffer (pH 7.6), which contained 0.1% sodium dodecyl sulfate (DNS), 0.5% Triton-X100, 0.15 M NaCl, 1 mM ethylene glycol tetraacetic acid (EGTA), 2.5 mM ethylenediaminetetraacetic acid (EDTA), 6.5 mM aprotinin, 1.5 mM pepstatin A, 23 μM leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 5 μg/mL soybean trypsin inhibitor. The homogenates were exposed thrice for 30 s to ultrasound with a Sartorius ultrasonic sonicator (Laboronic, M, Göttingen, Germany). The homogenates were centrifuged at 16,000 g for 30 min at 4 °C. Total protein content in the samples was determined by the Bradford method. The obtained protein extracts were used to determine the content of S100β, PARP and TNFα by western blot method. The samples of protein extracts (50 μg/track) were separated in gradient (5–20%) polyacrylamide gel electrophoresis (PAGE) according to the procedure described previously. The separated polypeptide zones were transferred by electroblot from PAGE to a nitrocellulose membrane with a pore diameter of 0.45 μm (GE Health care, Amersham Bioscience, RPN 203D). After transfer, the membranes were washed with phosphate saline buffer (PBS) and blocked in a 5% (w/v) solution of dry milk powder for 90 min at 37 °C. Incubation was conducted with primary antibodies anti-S100β (Abcam, ab52642, 1:2000), anti-PARP1 (Abcam, ab194586, 1:2500), anti-TNFα (Santa Cruz Biotechnology, sc-52746, 1:750), and anti-β-actin (Abcam, ab20272, 1:5000) diluted in PBS containing 0.05% Tween-20 (PBS-T)
for a night at 4 °C. After incubation with primary antibodies, the membranes were washed with PBS-T. The washed membranes were incubated with secondary antibodies (Sigma-Aldrich SA37000484, 1:10000) conjugated with horseradish peroxidase for 60 min at 37 °C and similarly washed with PBS-T after incubation.

Immunostaining of western blot results was developed with hemi-nanol-cumaric acid-hydrogen peroxide solution by the enhanced chemiluminescence method with using X-ray film (Konica Minolta, Japan). Densitometric analysis of western blot results was performed by using TotalLab TL120 software (USA). The intensity value which was obtained via scan of every studied protein band normalized to the intensity of the actin band of the corresponding sample. Every polypeptide band on the produced picture was corrected to background level, which conforms to nonreactive area on the X-ray film.

C60 hydrated fullerene solution. An aqueous solution of C60 hydrated fullerene (C60HyFn) was prepared from samples with a purity of at least 99.5% (MER Corporation, Tucson, AZ, USA) without any toxic organic thinners or/and chemical modification. The method of transferring fullerene from an organic solvent to the aqueous phase by ultrasound exposure allows one to obtain a solution of C60HyFn with a concentration of 5.5 × 10⁻³ M, depending on the concentration of C60HyFn, the solution contains both single fullerene molecules and their labile nanoclusters with sizes of 3–36 nm. In this work, C60HyFn concentration of 8.88 × 10⁻³ M was used as stock solution to prepare a working dilution of 30 nM (~20 ng/mL).

Statistical analysis of the data was performed with small-sample mathematical statistics methods using StatSoft Inc. application packages. The relative content of S100β, PARP and TNFα was expressed as mean x ± SE, the probability of the differences between studied groups was estimated using Student’s t-test (P < 0.05) after testing the hypotheses about the normality of distribution and the difference between the general variances.

Results

The results of measurements of glucose level in the blood of animals before the induction of STZ-diabetes and 12 weeks afterwards showed significant differences between the control and STZ-D which reflected the development of persistent hyperglycemia (Fig. 1). No significant difference in blood glucose level was detected between STZ-D and STZ-D + C60 animal groups. Thus, C60HyFn exposure did not affect blood glucose levels in diabetic rats.

On other hand, the blood insulin level of the STZ-D and STZ-D + C60 groups of diabetic animals was reduced by 1.57 and 1.32 times relative to the control, respectively (P > 0.05). The result, although statistically insignificant, may reflect a tendency for partial recovery of β-cells of the Langerhans islands by action of C60HyFn. However, this observation needs further experimental verification.

The content of glycosylated hemoglobin is a confirmed indicator of the abnormality in glucose utilization. Besides, glycosylated hemoglobin assessment was used as an additional criterion to verify the adequacy of the created model of STZ-diabetes. Glycosylated hemoglobin content was higher in the blood of the STZD group of rats compared to the control group (P < 0.05) (Table 1). However, glycosylated hemoglobin content in the STZD group of animals was observed to be 1.66 times lower than the corresponding content in STZD + C60 group (P < 0.05). Thus, prolonged consumption of C60HyFn may partially prevent metabolic disorders of glucose utilization.

Table 1

| The weight and insulin parameters | The time of induced hyperglycemia | Control (C) | Normal control, (C0) | Diabetic group, (STZ-D) | Diabetic group treated with C60HyFn, (STZ-D + C60) |
|---------------------------------|---------------------------------|-------------|---------------------|------------------------|-----------------------------------------------|
| Weight of animals, g           | 1st week                        | 210 ± 10.8  | 212 ± 10.7          | 211 ± 9.7              | 212 ± 10.5                                   |
|                                 | 2nd week                        | 305 ± 11.2  | 303 ± 14.2          | 251 ± 12.7             | 291 ± 13.7                                   |
| Insulin, µU/ml                 |                                 |             |                     |                        |                                              |
|                                 | 1st week                        | 449 ± 2.07  | 452 ± 2.43          | 201 ± 2.11**           | 204 ± 2.17**                                 |
|                                 | 2nd week                        | 459 ± 2.17  | 461 ± 1.98          | 201 ± 1.85**           | 34.8 ± 3.26**                                |

Note: * P < 0.05, ** P < 0.01 significance of differences compared with control group.

The results of S100β measurement in the retina of the control group and the animals exposed to C60HyFn, STZ-D and STZ-D + C60 showed significant changes (P < 0.01) of this glial marker protein in the diabetic group compared with both control and C60HyFn groups. Furthermore, the treatment of the STZ-D rat group with C60HyFn during 12 weeks prevented the increase of S100β (P < 0.05) in the retina of the diabetic rat group (Fig. 2). Taking into account that S100β is a marker of astrocytes, the determined changes of S100β content reflect astrogliosis suppression with fullerene nanoparticles.

The results of poly-(ADP-ribose) polymerase (PARP) assessment in the retinal extracts of the control group and the control rats exposed to C60HyFn, the STZ-D and STZ-D + C60 groups showed changes similar to S100β (P < 0.01) of this universal marker of cellular reactivity against oxidative damage of DNA in the diabetic group compared with the control one. By contrast, treatment with C60HyFn of the diabetic rat group during 12 weeks provided a decrease of PARP in the retina compared to the untreated diabetic rat group (Fig. 3). Thus, fullerene can abrogate PARP upregulation in retinal cells.

The changes in tumour necrosis factor alpha (TNFα) content determined in the retinal extracts of the control group and the control rats exposed to C60HyFn, the STZ-D and STZ-D + C60 groups showed the meaningful increment of this pro-inflammatory factor production in the STZ-D group in comparison to the control one. On other hand, the exposure of STZ-D rats to C60HyFn during 12 weeks prevented the overproduction of TNFα in the retina of diabetic rats compared to the untreated STZ-D
animal group (Fig. 4). The presented results demonstrate anti-inflammatory effect of C60HyFn in retina of diabetic rats.

![Graph](image_url)

**Fig. 3. Relative content of PARP in the retina of control (C), control treated with C60HyFn (C60), STZ (STZ-D) and STZ-D + C60 groups of animals 12 weeks after diabetes initiation:**

- **P < 0.05** significance of differences compared with control group,
- **P < 0.05** significance of differences compared with STZ-D

It needs to be mentioned that every studied marker of cellular response reflected the suppression of cellular reactivity in the retina of the rats with STZ-induced hyperglycemia. The results of western blot for S100β, PARP and TNFα have demonstrated a decrease in the content of all of them (Fig. 5). Western blot results for S100β, PARP and TNFα were calculated as the relation of intensity of immunostaining of every zone to corresponding intensity of β-actin zone.

**Discussion**

The leading role of oxidative damage and pro-inflammatory factors in DR progression has been widely reported in recent decades. However, the modern approaches to treatment as well as prevention of DR initiation in the diabetic patient cohort are not effective to an adequate degree and limited by various factors (Frank, 2009; Hernandez et al., 2016; Amato et al., 2018). Hyperglycemia initiates various molecular and cellular abnormalities which initiate sustained disbalance in metabolic energy expenditure (Ola et al., 2012). Clarification of reactivity of astroglial cells as well as the role of critical molecular pathways in retinal dysfunction will make it possible to construct an effective therapeutic strategy for DR treatment. Diabetic complications closely relate to consequent critical disturbances as a result of the high glucose level: the switching of glucose utilization to the polyol pathway, formation of advanced glycation-end products (AGES), neuroinflammation, oxidative stress and excitotoxicity (Asnaghi et al., 2003; Sanchez-Chavez et al., 2016; Amato et al., 2018).

Taking into account that S100β is a valid astrocyte marker, the results obtained in the presented study showing an increase of S100β content evidence the generation of astrogliosis in the retina of diabetic rats. The data obtained in our study agree with the recently described results on upregulation of both S100 and glial fibrillary acidic protein (GFAP) astrogial markers expression (Abu El-Azar et al., 2014; Nedzvetski et al., 2016). Furthermore, the authors demonstrated that S100 expression was upregulated in human retinal microvascular endothelial cells (HRMECs) by the exposure to TNF-α (Abu El-Azar et al., 2014).

S100β protein is a member of the Ca<sup>2+</sup>-binding protein family which has preferential astrocytic location (Donato et al., 2009). Numerous data evidence that S100β activity is similar to that of Damage-Associated Molecular Pattern protein and this protein is capable of activating cellular response (Sorci et al., 2010; Bianchi et al., 2011). However, the data on S100β participation in retinal disturbances are extremely limited. Kim and colleagues described functional interaction between S100β and GFAP in the course of response to kainate injury (Kim et al., 2003). Besides, overexpression of GFAP in the brain of animals with experimentally induced diabetes was demonstrated in various brain areas (Nedzvetski et al., 2012). Various types of brain injury provoke release of S100 family proteins into cerebrospinal fluid and blood (Rothermundt et al., 2003; Michetti et al., 2012), which allows this glial marker to be used as a diagnostic tool to determine CNS damage (Gerrlach et al., 2006; Ellis et al., 2007; Mazzone & Nistri, 2014). Several in vitro results have demonstrated that S100β efflux, which was stimulated with oxygen-glucose deprivation and metabolic stress, is independent of the synthesis S100β protein de novo (Davey et al., 2001; Gerrlach et al., 2006; Ellis et al., 2007). In addition, S100β protein can be involved into intracellular regulation of Ca<sup>2+</sup>-dependent proteases as well as into extracellular signalling (Donato et al., 2009). Both of these activities are associated with astroglial reactivity.

The role of inflammatory disturbances in DR is confirmed by several data of both in vivo and in vitro study (Tang, 2011; Luo et al., 2015; Wang et al., 2019). In this study we used the measurement of TNFα content to evaluate pro-inflammatory changes in the retina of animals with 12 week STZ-induced diabetes. According to the results obtained, the expression of TNFα in the retina of the STZ-D animal group was statistically increased as compared to the control ones. Thus, the results observed on the increment of pro-inflammatory cytokine TNFα in the STZ-D animal group attest the evident fact that hyperglycemia induces chronic (12 weeks) inflammation in the retina. In view of data on the capability of TNFα to stimulate expression of several members of the S100 protein family (Abu El-Azar et al., 2014), we can presume that S100β participation in retinal astrogliosis of diabetic rats is at least partially dependent on local inflammation in retinal glial cells.

Astrocytes provide physical support and supply neurons with various metabolites, regulate synaptic transmission, form the blood brain

![Graph](image_url)

**Fig. 5. Relative content of TNFα in the retina of control (C), control treated with C60HyFn (C60), STZ (STZ-D) and STZ-D + C60 groups of animals 12 weeks after diabetes initiation**

- **P < 0.05** significance of differences compared with control group,
- **P < 0.05** significance of differences compared with STZ-D

Discussion

The leading role of oxidative damage and pro-inflammatory factors in DR progression has been widely reported in recent decades. However, the modern approaches to treatment as well as prevention of DR initiation in the diabetic patient cohort are not effective to an adequate degree and limited by various factors (Frank, 2009; Hernandez et al., 2016; Amato et al., 2018). Hyperglycemia initiates various molecular and cellular abnormalities which initiate sustained disbalance in metabolic energy expenditure (Ola et al., 2012). Clarification of reactivity of astroglial cells as well as the role of critical molecular pathways in retinal dysfunction will make it possible to construct an effective therapeutic strategy for DR treatment. Diabetic complications closely relate to consequent critical disturbances as a result of the high glucose level: the switching of glucose utilization to the polyol pathway, formation of advanced glycation-end products (AGES), neuroinflammation, oxidative stress and excitotoxicity (Asnaghi et al., 2003; Sanchez-Chavez et al., 2016; Amato et al., 2018).
barrier (BBB) as well as the blood-retinal barrier (BRB) (Wang & Bordes, 2008; Sofroniew & Vinters, 2010; Mathiesen et al., 2010). Astrocytes respond to all forms of insult in the brain via unspecific reactivity named astrogliosis (Sofroniew, 2014). Reactive astrocytes produce cytokines and are drivers of oxidative stress (Wang et al., 2012). In addition, high glucose also initiates release of inflammatory cytokines and alters the retinal astrocytes' phenotype through astrogliosis (Shin et al., 2014). Furthermore, hyperglycemia-induced disturbances in retinal metabolism initiate reactive astrogliosis and as result decline of critical glial functions including transformation of glucose into lactate and its delivery to neurons (Wang et al., 2012; Shin et al., 2014). Anatomically the transport of glucose from blood is realized through astrocytes because they are a critical component of the BBB (Pellerin, 2018). Hyperglycemia can directly initiate impact on the metabolism and function of astrocytes (Li et al., 2018). However, which cell types, especially neurons or glial cells, are more important in initiating the functional decline in the brain exposed to high glucose remains debatable.

Taking into account that astrocytes are the critical participants which provide neuronal energy metabolism, the expenditure of energy to provide glial reactivity can initiate the starvation of neurons. Thus, chronic or meaningful reactivity of astrocytes can induce neuronal dysfunction through a lack of energy substrate supply. However, all hyperglycemia-induced molecular and cellular abnormalities require the expenditure of metabolic energy, especially switching glucose utilization onto the polyol pathway leading to a lack of ATP production.

It is worth mentioning that PARP activation plays an important role in vascular complications and endothelial dysfunction in the course of retinopathy development (Pacher et al., 2002). The role of PARP reactivity in the oxidative stress-initiated development of diabetic retinopathy was considered using PARP inhibitors, including 3-aminobenzamide and 1,5-isoquinolinediol (Obrosova et al., 2004). The authors observed the retinal VEGF abundance in diabetic rats and the increase of this angiogenesis stimulator in diabetic rats treated with PARP inhibitors. The reactivity of PARP which accompanied diabetic retinopathy is determined in the whole retina including endothelial cells, glial cells and pericytes of diabetic rats (Zheng et al., 2004). This hypothesis has been demonstrated in hyperglycemia-induced methylation of PARP1 promoter (Bai et al., 2015). Epigenetic regulation, especially induced by oxidative damage, or by active DNA methylation can play the critical role in DR progression where NF-κB is involved in Rac1 activation in retinal microvesicles (Dunaisamy et al., 2018). Taking into account that hyperglycemia can stimulate functional cooperation of PARP with transcriptional factor NF-κB (Zheng et al., 2004), we can presume the efficacy of PARP inhibition which are spread on suppression of NF-κB activity as well. The involvement of PARP into NF-κB-mediated retinal inflammation has been demonstrated by Lou and coauthors in a human retinal endothelial cells (HRECs) model and retina of diabetic rats (Luo et al., 2015).

Beneficial anti-diabetic effects were described in the past decade regarding natural antioxidants including resveratrol, hesperitin, curcumin and flavonoids (Kowluru et al., 2007; Soufi et al., 2012; Kumar et al., 2013; Ola et al., 2018). It was demonstrated that carotenoids containing nutritional supplements can prevent diabetic retinopathy, support retinal function and ameliorate pro-inflammatory mediators release via suppression of NF-κB activity (Kowluru et al., 2014). Unfortunately, the amount of data on the application of unmodified C₆₀ fullerene to treat diabetes complications is extremely limited. Recently the efficacy of C₆₀-HyFn was demonstrated with respect to the suppression of astrogliosis in the retina and hippocampus of diabetic rats (Nedzvetsky et al., 2012, 2016) and reproductive dysfunction (Bal et al., 2011). The exposure to C₆₀-HyFn in drinking water with concentration of 60 nM ameliorated upregulation of GFAP expression induced in the retina of STZ-diabetic rats. In this study the animals were exposed to C₆₀-HyFn in a dose of 30 nM, which prevented S100β overexpression and respectively astrogliosis as well.

Proinflammatory changes in DR attracts the attention of researchers no less than oxidative stress (Kowluru et al., 2007; Kumar et al., 2013). It deserves to be mentioned that retinal inflammation can initiate molecular and cellular injury as well as functional decline. In our opinion, there are no literature data concerning the anti-inflammatory effect of carbon nanoparticles in DR. However, anti-inflammatory effects of C₆₀ (nC₆₀) aqueous dispersion were evaluated in the mouse models of atopic dermatitis (Shershakova et al., 2016). The suppression of Th2 derived cytokines production was observed in mice sensitized with ovalbumin and exposed for 50 days to C₆₀ fullerene as compared to the mouse group with experimental dermatitis.

DR has long been predominantly considered as a vascular disorder which is accompanied by retinal vasculature disturbance (Ajlan et al., 2016). Indeed, a number of results have demonstrated increased VEGF level in DR, which induces aberrant vascular proliferation and disruption of the blood retinal barrier (Ola et al., 2012; Ajlan et al., 2016)

However, several observations have shown evident neuronal death in the retina of diabetic patients as well as various DR models (Tarr et al., 2013; Jindal, 2015; Hernandez, 2016). Therefore, a neuroprotective strategy to treat DR could be an effective part of combined therapy (Barber, 2003; Hernandez, 2016). Taking into account that neuroprotective efficacy of C₆₀ was demonstrated in different models of neurotoxicity including STZ-induced diabetes, the findings of this study have demonstrated the glitoprotective and anti-inflammatory effect of C₆₀ in the retina of rats affected by hyperglycemia for 12 weeks.

Chronic exposure to C₆₀ of the treated STZ-D rat group induced decrease of S100 in comparison to the untreated STZ-D group. On other hand, similar exposure to C₆₀ of the animals of the normal control group did not change S100 content in the retina. Therefore, C₆₀ exposure prevents astrogliosis in the retina of diabetic rats and develops glitoprotective effect. Furthermore, in accordance with the observed results exposure to C₆₀ shows a decrease in TNFα production, which also reflects the inhibition of retinal glial cells' reactivity.

Water soluble C₆₀-HyFn can penetrate the BBB and affect neural tissue cells as an anti-oxidant and anti-inflammatory agent. Oxidative stress and its consequences can form a crossroad between metabolic pathway abnormalities in DR. Furthermore, the interactions between the fundamental pathways of cellular response including synthesis of pro-inflammatory factors, antioxidan system and mitochondrial activity have multiple feedback regulation. Therefore, various targeted exposures can ameliorate DR pathogenesis, which is related to the above men-
tioned disturbances, including oxidative stress, inflammation, excitotoxicity and lack of metabolic energy (Amato et al., 2018). Anyway, oxidative damage, decline of metabolic energy and overactivity of inflammatory response remain leading drivers of diabetic complications. The results produced in our study demonstrated significant suppression of TNF production in the retina of the STZ-D group exposed to C60HyFn compared to the untreated diabetic group. Thus, C60HyFn developed anti-inflammatory efficacy in hyperglycemia-induced abnormalities in the retina of STZ-D animals. Taking together the above mentioned results on the upregulation of all S100B, PARP1 and TNFα in the retina of STZ-D animals, we can conclude that our diabetic model re-creates DR complications. Our findings on chronic exposure of STZ-D rats to C60HyFn in drinking water showed ameliorated content all the studied markers of cellular viability. Thus, hyperglycemia-induced abnormalities in the retina of STZ-D rats were suppressed via the anti-oxidant, anti-inflammatory and glitoprotective effects of C60HyFn in low doses. The findings support the hypothesis that C60 fullerene can prevent metabolic energy expenditure in the course of early stage DR through inhibition of both PARP1 activity and astrogliosis. Thus, C60HyFn can support viability of retinal cells and develop neuroprotective effect. Therefore, nanoparticles of C60HyFn which combine anti-oxidant and anti-inflammatory effects in DR treatment could form the basis of a new therapeutic strategy of DR treatment.

Conclusion

As presented in this study, the anti-oxidant, anti-inflammatory and glitoprotective effects of C60HyFn in the retina of STZ-diabetic rats confirm the potential of fullerene to be an effective agent as a therapeutical supplement to prevent diabetic retinopathy. Further studies are relevant and extremely necessary to clarify neuroprotective effects of carbon nanoparticles.

References

Abu El-Asrar, A. M., Nawaz, M. I., De Hertogh, G., Alam, K., Siddiquei, M. M., Van den Eynde, K., Mousa, A., Mohanna, G., Geboes, K., & Opdenakker, G. (2014). S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Molecular Vision, 20, 1209–1224.

Ajlan, R. S., Silva, P. S., & Sun, J. K. (2016). Vascular endothelial growth factor and diabetic retinal disease. Seminars in Ophthalmology, 31, 40–48.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Andreev, S., Purgina, D., Struchkova, I., Kamyshnikov, O., Nikonova, A., & Vetsky, V. S., Tykhomyrov, A. A., Andrievsky, G. V., Baydas, G., & Nazirov, A. A. (2016). Active secretion of S100B from astrocytes during inflammation in retinal Muller glia under chronic hyperglycemia: Implications for diabetic retinopathy. Experimental Diabetes Research, 43(8), 238.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Asnaghi, V., Gerhardinger, C., Hoehn, T., Adeboje, A., & Lorenzi, M. (2003). A C60HyFn can support viability of retinal cells and develop neuroprotective effect. Therefore, nanoparticles of C60HyFn which combine anti-oxidant and anti-inflammatory effects in DR treatment could form the basis of a new therapeutic strategy of DR treatment.

References

Abu El-Asrar, A. M., Nawaz, M. I., De Hertogh, G., Alam, K., Siddiquei, M. M., Van den Eynde, K., Mousa, A., Mohanna, G., Geboes, K., & Opdenakker, G. (2014). S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Molecular Vision, 20, 1209–1224.

Ajlan, R. S., Silva, P. S., & Sun, J. K. (2016). Vascular endothelial growth factor and diabetic retinal disease. Seminars in Ophthalmology, 31, 40–48.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Andreev, S., Purgina, D., Struchkova, I., Kamyshnikov, O., Nikonova, A., & Vetsky, V. S., Tykhomyrov, A. A., Andrievsky, G. V., Baydas, G., & Nazirov, A. A. (2016). Active secretion of S100B from astrocytes during inflammation in retinal Muller glia under chronic hyperglycemia: Implications for diabetic retinopathy. Experimental Diabetes Research, 43(8), 238.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Asnaghi, V., Gerhardinger, C., Hoehn, T., Adeboje, A., & Lorenzi, M. (2003). A C60HyFn can support viability of retinal cells and develop neuroprotective effect. Therefore, nanoparticles of C60HyFn which combine anti-oxidant and anti-inflammatory effects in DR treatment could form the basis of a new therapeutic strategy of DR treatment.

Conclusion

As presented in this study, the anti-oxidant, anti-inflammatory and glitoprotective effects of C60HyFn in the retina of STZ-diabetic rats confirm the potential of fullerene to be an effective agent as a therapeutical supplement to prevent diabetic retinopathy. Further studies are relevant and extremely necessary to clarify neuroprotective effects of carbon nanoparticles.

References

Abu El-Asrar, A. M., Nawaz, M. I., De Hertogh, G., Alam, K., Siddiquei, M. M., Van den Eynde, K., Mousa, A., Mohanna, G., Geboes, K., & Opdenakker, G. (2014). S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Molecular Vision, 20, 1209–1224.

Ajlan, R. S., Silva, P. S., & Sun, J. K. (2016). Vascular endothelial growth factor and diabetic retinal disease. Seminars in Ophthalmology, 31, 40–48.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Andreev, S., Purgina, D., Struchkova, I., Kamyshnikov, O., Nikonova, A., & Vetsky, V. S., Tykhomyrov, A. A., Andrievsky, G. V., Baydas, G., & Nazirov, A. A. (2016). Active secretion of S100B from astrocytes during inflammation in retinal Muller glia under chronic hyperglycemia: Implications for diabetic retinopathy. Experimental Diabetes Research, 43(8), 238.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Asnaghi, V., Gerhardinger, C., Hoehn, T., Adeboje, A., & Lorenzi, M. (2003). A C60HyFn can support viability of retinal cells and develop neuroprotective effect. Therefore, nanoparticles of C60HyFn which combine anti-oxidant and anti-inflammatory effects in DR treatment could form the basis of a new therapeutic strategy of DR treatment.

Conclusion

As presented in this study, the anti-oxidant, anti-inflammatory and glitoprotective effects of C60HyFn in the retina of STZ-diabetic rats confirm the potential of fullerene to be an effective agent as a therapeutical supplement to prevent diabetic retinopathy. Further studies are relevant and extremely necessary to clarify neuroprotective effects of carbon nanoparticles.

References

Abu El-Asrar, A. M., Nawaz, M. I., De Hertogh, G., Alam, K., Siddiquei, M. M., Van den Eynde, K., Mousa, A., Mohanna, G., Geboes, K., & Opdenakker, G. (2014). S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Molecular Vision, 20, 1209–1224.

Ajlan, R. S., Silva, P. S., & Sun, J. K. (2016). Vascular endothelial growth factor and diabetic retinal disease. Seminars in Ophthalmology, 31, 40–48.

Amato, R., Dal Monte, M., Lulli, M., Raffa, V., & Casini, G. (2018). Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Current Neuropharmacology, 16(7), 993–1003.

Andreev, S., Purgina, D., Struchkova, I., Kamyshnikov, O., Nikonova, A., & Vetsky, V. S., Tykhomyrov, A. A., Andrievsky, G. V., Baydas, G., & Nazirov, A. A. (2016). Active secretion of S100B from astrocytes during inflammation in retinal Muller glia under chronic hyperglycemia: Implications for diabetic retinopathy. Experimental Diabetes Research, 43(8), 238.
